The United States Patent and Trademark Office has issued U.S. Patent No. 12,544,407 B2 , dated February 10, 2026, further strengthening FibroBiologics’ intellectual property portfolio in regenerative ...

FibroBiologics is planning a prospective, multicenter, open-label clinical trial evaluating the safety, tolerability, and efficacy of CYWC628 in treating refractory diabetic foot ulcers with up to 12 ...

Successful wound healing relies on precisely balanced inflammation, yet how inflammatory signals are coordinated over time ...

In a significant breakthrough in inflammatory arthritis research, a study published today (Feb. 23) in Nature Immunology has revealed that inflammation-associated fibroblasts—a type of cell in ...

Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.

Genetic data linked FGF21 signalling to lower problematic alcohol use and ARLD risk. Learn how this liver–brain pathway may reshape treatment.

Helmholtz Munich researchers revealed a conserved differentiation process with clinical implications for injury repair, identifying a multipotent fibroblast progenitor in the fascia— the deepest ...

In a collaboration between several labs at UNC Lineberger, researchers have defined cancer-associated fibroblast (CAF) subtypes that are clinically robust, prognostic, and predictive of immunotherapy ...

Secured both public and private Human Research Ethics Committee (HREC) approvals in Australia for a Phase 1/2 clinical trial evaluating CYWC628 for the treatment of refractory diabetic foot ulcers ...